This June 2026 notification signals a maturing pharmacovigilance framework. For stakeholders from large-scale manufacturers and CMOs to frontline healthcare providers, the message is clear: scientific justification is the only path to market survival. This article breaks down the ban and explores the strategic shifts necessary for industry compliance.